Chronic myeloid leukemia in the Imatinib era-Compilation of Indian data from 22 centers involving 8115 patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Chronic myeloid leukemia in the Imatinib era-Compilation of Indian data from 22 centers involving 8115 patients ; volume:34 ; number:03 ; year:2013 ; pages:145-146
Indian journal of medical & paediatric oncology ; 34, Heft 03 (2013), 145-146
- Contributor
-
Parikh, Purvish
Bansal, Shweta
- DOI
-
10.4103/0971-5851.123699
- URN
-
urn:nbn:de:101:1-2021083013191839711476
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Parikh, Purvish
- Bansal, Shweta
Other Objects (12)
Imatinib Mesylate in Chronic Myeloid Leukemia
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients
Imatinib Mesylate in Chronic Myeloid Leukemia
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients
Imatinib Mesylate in Chronic Myeloid Leukemia
Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia
Imatinib Mesylate in Newly Diagnosed Patients of Chronic Myeloid Leukemia
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia
Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV